While IL-17 is known to have double-edged features—where in early tumor development, IL-17 promotes tumor growth, while in later stages, it has been shown to enhance cytotoxic T cells (CD8+) to generate an anti-tumor effect and is positively correlated with survival in human adenocarcinoma [33]. The gene discussed is CD8A; the disease is adenocarcinoma.